喹齐酮
喹齐酮结构式
|
常用名 | 喹齐酮 | 英文名 | Quazinone (Ro 13-6438) |
|---|---|---|---|---|
| CAS号 | 70018-51-8 | 分子量 | 235.67000 | |
| 密度 | 1.57g/cm3 | 沸点 | 345.6ºC at 760 mmHg | |
| 分子式 | C11H10ClN3O | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | 162.8ºC |
|
Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model.
J. Biomol. Screen. 11(5) , 457-68, (2006) The squamous cell carcinoma HeLa cell line and an epithelial cell line hTERT-RPE with a nonmalignant phenotype were interrogated for HeLa cell selectivity in response to 1267 annotated compounds representing 56 pharmacological classes. Selective cytotoxic act... |
|
|
Role of cGMP-inhibited phosphodiesterase and sarcoplasmic calcium in mediating the increase in basal heart rate with nitric oxide donors.
J. Mol. Cell. Cardiol. 32(10) , 1831-40, (2000) Nitric oxide (NO) donors increase heart rate (HR) through a guanylyl cyclase-dependent stimulation of the pacemaker current I(f), without affecting basal I(Ca-L). The activity of I(f)is known to be enhanced by cyclic nucleotides and by an increase in cytosoli... |
|
|
Relaxation of human ureteral smooth muscle in vitro by modulation of cyclic nucleotide-dependent pathways.
Urol. Res. 28(2) , 110-5, (2000) Phosphodiesterases (PDE) are key enzymes regulating intracellular cyclic nucleotide turnover and, thus, smooth muscle tension. Recent reports have indicated the presence of PDE isoenzymes 1, 2, 4, and 5 in cytosolic supernatants prepared from human ureteral s... |
|
|
HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.
Life Sci. 31 , 2037, (1982) The new pyrimido-isoquinoline compound HL 725 is an extremely potent inhibitor of the aggregation of human platelets induced in vitro by ADP, collagen, thrombin and epinephrine. The aggregation induced by 0,5 mM arachidonic acid is inhibited about 50% with 50... |
|
|
Survival in severe left ventricular failure treated with the new nonglycosidic, nonsympathomimetic oral inotropic agents.
Chest 92(1) , 118-23, (1987) Survival in severe left ventricular failure is poor but has not been widely assessed since the introduction of several new nonglycosidic, nonsympathomimetic oral inotropic agents for long-term therapy. We examined retrospectively the survival of 82 patients w... |
|
|
Effects of mitogen-activated protein kinase inhibitors or phosphodiesterase inhibitors on interleukin-1-induced cytokines production in synovium-derived cells.
Immunol. Lett. 68(2-3) , 275-9, (1999) The effects of mitogen-activated protein (MAP) kinase inhibitors or phosphodiesterase (PDE) inhibitors on interleukin (IL)-1-induced cytokines production in synovium-derived cells were investigated. Human synoviocyte (HS) or synovial sarcoma (SW982) stimulate... |
|
|
Phosphodiesterase isoenzymes in human ureteral smooth muscle: identification, characterization, and functional effects of various phosphodiesterase inhibitors in vitro.
Urol. Int. 55(4) , 183-9, (1995) Phosphodiesterases (PDE) are key enzymes regulating intracellular cyclic nucleotide metabolism and, thus, contraction and relaxation of the muscle. At present, five different families of isoenzymes of PDE exist that show a distinct species-specific and organ-... |
|
|
RO 13-6438 in congestive heart failure: dose-response relationship after 3 single doses.
Fundam. Clin. Pharmacol. 1(6) , 459-70, (1987) The dose-response for the new cardiotonic agent RO13-6438 was studied in 6 patients with grade III or IV congestive heart failure. Oral doses of 10, 20, or 30 mg of RO 13-6438 were administered on 3 consecutive days in accordance with a double-blind, randomiz... |
|
|
[New cardiotonic agents].
Ann. Cardiol. Angeiol. (Paris.) 34(10) , 681-8, (1985) The possibilities for therapy in the field of severe cardiac insufficiency have been extended in recent years by the introduction of novel agents endowed with a positive inotropic action. These substances may be arranged in two large classes: sympathomimetic ... |
|
|
[Positive inotropic therapy of cardiac failure: old and new drugs, controversies and tests].
Clin. Ter. 111(2) , 159-67, (1984)
|